Referência de medicamentos
Empagliflozin-linagliptin-metformin
Empagliflozin-linagliptin-metformin is a medicine in the class gastrointestinal tract. It is used for diabetes mellitus.
- Classe do medicamento: Gastrointestinal Tract
- Indicado para: diabetes mellitus
Última atualização
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Pontos-chave
- Classe do medicamento
- Gastrointestinal Tract
- Formas farmacêuticas comuns
- comprimido
- Concentrações comuns
- 1000 mg
- Nomes comerciais
- 7
- Países e mercados
- 2
Para que é usado
Como funciona
Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion
Dose habitual em adultos (resumo da bula)
Type 2 Diabetes Mellitus: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM)
Gravidez e amamentação
- Gravidez
- Unsafe Based on animal data showing adverse renal effects from empagliflozin, use is not recommended during the second and third trimesters of pregnancy
- Amamentação
- Unsafe Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney, advise patients that use is not recommended while breastfeeding
Efeitos adversos relatados
- Nasopharingitis
- Constipation
- Gastroenteritis
- Urinary tract infections
- Hypoglycaemia
- Diarrhea
Advertências de caixa preta
- Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress, somnolence, abdominal pain) Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL Risk factors include…
Contraindicações
- Hypersensitivity to empagliflozin, linagliptin, metformin, or any of the excipients in the product
- Metabolic acidosis, including diabetic ketoacidosis
- Severe renal impairment (eGFR <30 mL/min/1.73 m2), ESRD, or dialysis
Quem deve ter cuidado
- Serious hypersensitivity reactions, (eg, angioedema) in patients treated with empagliflozin reported postmarketing; discontinue therapy and treat promptly if it occurs per standard of care
- There have been reports of acute pancreatitis, including fatal pancreatitis; if pancreatitis suspected, promptly discontinue
- Heart failure observed with 2 other DPP-4 inhibitors; consider risks and benefits in patients with known risk factors for heart failure; monitor for signs and symptoms
Informe ao farmacêutico ou ao médico sobre gravidez ou amamentação, doença renal ou hepática, alergias e todos os outros medicamentos ou suplementos que você usa.
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para abrir a monografia completa de Empagliflozin-linagliptin-metformin: doses, gravidez e amamentação, efeitos adversos, advertências e todas as interações.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Experimente o Pro+ grátis por 14 dias na web. Sem cartão.
Outros medicamentos desta classe
Perguntas frequentes
What is Empagliflozin-linagliptin-metformin used for?
Empagliflozin-linagliptin-metformin is a medicine in the class gastrointestinal tract. It is used for Diabetes mellitus.
What side effects have been reported with Empagliflozin-linagliptin-metformin?
Nasopharingitis, Constipation, Gastroenteritis, Urinary tract infections, Hypoglycaemia, Diarrhea. Serious warning: Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress,…
Can Empagliflozin-linagliptin-metformin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Based on animal data showing adverse renal effects from empagliflozin, use is not recommended during the second and third trimesters of pregnancy Breastfeeding: Unsafe. Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney, advise patients that use is not recommended while breastfeeding
What does Empagliflozin-linagliptin-metformin interact with?
MediHelp does not list a checked interaction for Empagliflozin-linagliptin-metformin yet. Always tell your pharmacist about every medicine you take.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
